What Is GLP-2? Teduglutide, Intestinal Growth, and Gut Barrier Research

GLP-2 is not a metabolic peptide in the GLP-1 sense — it does not touch insulin secretion or appetite in any meaningful way. It is a gut-growth signal, one of the most extensively studied intestinotrophic hormones in the physiology literature, and it happens to be one of the few peptide research compounds in this category with an actual FDA-approved clinical analog: teduglutide (marketed as Gattex in the US and Revestive in the EU). That makes GLP-2 biology unusually well documented — villus and crypt architecture, growth-factor cascades, and gut-barrier effects have all been characterized in peer-reviewed rodent and human studies. This article summarizes that literature for research and laboratory context only. Nothing here describes or endorses human use of any research compound.

GLP-2: An Intestinotrophic Hormone

Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid peptide co-secreted with GLP-1 from intestinal enteroendocrine L-cells, both derived from post-translational cleavage of the same proglucagon precursor. Where GLP-1 research centers on insulin and gastric emptying, GLP-2 research centers on the gut wall itself. It is classified as intestinotrophic — meaning its defining pharmacologic property, first demonstrated by Drucker and colleagues in 1996 and replicated repeatedly since, is stimulation of small and large intestinal mucosal growth in rodent models. Research reviews describe GLP-2 receptor signaling as acting indirectly: the receptor is expressed on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons rather than on the proliferating crypt cells themselves, which is why its effects are mediated through a network of downstream growth factors rather than a direct mitogenic action on epithelium.

Teduglutide and the Short Bowel Syndrome Anchor

The clinical translation of GLP-2 biology is teduglutide, a recombinant human GLP-2 analog. The FDA approved teduglutide (Gattex) in December 2012 for adults with short bowel syndrome (SBS) who remain dependent on parenteral (intravenous) nutritional support, and extended that approval to pediatric patients one year and older in 2019. In the approved clinical population it is prescribed as a once-daily subcutaneous injection, with the mechanism described in the prescribing literature as restoration of intestinal structural and functional integrity — increased mucosal growth, increased intestinal and portal blood flow, and reduced gastric emptying and secretion, together improving fluid and nutrient absorption enough to reduce reliance on parenteral nutrition in trial populations. This is the only reason GLP-2 pharmacology exists in human medicine at all: it is a narrow, orphan-disease indication, not a general metabolic or wellness therapy. Every fact in this article traces back to that clinical anchor and the preclinical work that preceded it — none of it describes or endorses use outside a regulated clinical or laboratory setting.

The Gly2 Substitution and DPP-4 Resistance

Native GLP-2 has a very short circulating half-life — on the order of about 7 minutes in humans — because it is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4), which clips the peptide at its N-terminal dipeptide bond. Medicinal chemistry work aimed at extending that half-life identified a single amino-acid substitution — replacing the alanine at position 2 with glycine (the Gly2 substitution) — that renders the peptide resistant to DPP-4 cleavage. Reported in vitro data describe the [Gly2]-GLP-2 analog (the molecule that became teduglutide) as remaining essentially fully intact after 24-hour incubation with purified DPP-4 and rat plasma, a stark contrast to native GLP-2's minutes-long stability window. In preclinical pharmacokinetic characterization, this substitution extends the effective half-life from roughly 7 minutes for native GLP-2 to roughly 1.3–2 hours for the analog — the modification that made once-daily dosing in the teduglutide clinical program feasible in the first place. This is a textbook example of how a single-residue substitution can convert a fragile endogenous peptide into a pharmacokinetically viable research or clinical molecule, and it parallels DPP-4-resistance strategies used elsewhere in peptide pharmacology (for example, in GLP-1 analog design).

Villus Height, Crypt Depth, and Mucosal Growth

The core intestinotrophic phenotype has been quantified histologically in multiple rodent studies. In one reported protocol, sustained twice-daily administration of GLP-2 or teduglutide to mice over 14 days produced an approximately 30% increase in small intestinal wet weight alongside measurable increases in villus height and crypt depth. In that same body of work, GLP-2 administration in a BDF1 mouse cohort was associated with increases in crypt height and area (roughly 11% and 24%, respectively) and villus height and area (roughly 8% and 15%, respectively); teduglutide produced comparable or larger increases in the same strain. Reported magnitudes vary by mouse strain and dosing protocol, underscoring that these are strain- and study-specific figures rather than universal constants. Mechanistically, this growth reflects increased crypt cell proliferation combined with decreased epithelial apoptosis along the crypt-villus axis — the two cellular processes that jointly determine mucosal surface area. Human short bowel syndrome patients biopsied during teduglutide clinical trials showed a similar histological signature — one published phase II study reported mean increases in villus height (~38%) and crypt depth (~22%) relative to baseline, which researchers link mechanistically to the drug's effect on nutrient absorption. It is worth being explicit that villus/crypt morphometry of this kind is a histology endpoint scored in animal tissue sections or clinical biopsy specimens — it is not something inferred or self-assessed outside a laboratory or clinical setting.

Growth Factors: IGF-1, EGF, and KGF

Because the GLP-2 receptor is not expressed on the proliferating crypt cells themselves, its trophic effects are relayed through a set of secondary growth factors released by neighboring cell types — a mechanism researchers have sometimes called the peptide's "cryptic" mode of action. In the small intestine, the dominant relay involves insulin-like growth factor-1 (IGF-1): GLP-2 stimulates IGF-1 mRNA expression and secretion from intestinal subepithelial myofibroblasts, and studies using IGF-1- and intestinal-epithelial-IGF-1-receptor-deficient mouse models show that this signaling axis is required for GLP-2's crypt cell proliferation and small-bowel growth response. Epidermal growth factor (EGF) signaling acts alongside IGF-1 in this pathway — reported work shows GLP-2's proliferative effect is augmented by exogenous EGF in a manner that is partially dependent on intestinal epithelial IGF-1 receptor signaling. In the colon, a distinct relay predominates: GLP-2 stimulates colonic growth via keratinocyte growth factor (KGF), released by GLP-2-receptor-bearing subepithelial myofibroblasts, and antibody-blockade studies show KGF neutralization abolishes GLP-2's colonic — but not small-intestinal — growth effect. This regional division — IGF-1/EGF driving small bowel growth, KGF driving colonic growth — is one of the more consistent findings across the GLP-2 mechanistic literature.

Gut Barrier and Tight-Junction Research

Beyond raw mucosal growth, a separate line of research has examined GLP-2's effect on intestinal barrier integrity — the tight-junction network that governs paracellular permeability between epithelial cells. In mice, GLP-2 treatment reduced permeability to a 4-kDa FITC-dextran tracer and increased jejunal tissue electrical resistance; these effects tracked with upregulation of the tight-junction proteins claudin-3 and claudin-7 and with proper apical localization of occludin, and all of them were lost in mice lacking the intestinal epithelial IGF-1 receptor — linking the barrier-protective and mucosal-growth actions of GLP-2 to the same signaling pathway. A separate line of in vitro work used Caco-2 monolayers — a standard human intestinal epithelial cell-culture barrier model — and found that GLP-2 exposure increased transepithelial electrical resistance and upregulated occludin and zonula occludens-1 (ZO-1), substantially blunting the drop in resistance normally caused by the inflammatory cytokine TNF-alpha. Together, this body of work positions GLP-2 as a peptide of interest in gut-barrier and mucosal-integrity research more broadly, distinct from its narrower clinical use in short bowel syndrome.

Research Use Only

Everything above describes preclinical rodent data, in vitro cell-culture models, and the clinical trial record for the FDA-approved drug teduglutide in a specific orphan indication (short bowel syndrome). None of it constitutes, implies, or should be read as guidance for administering any peptide to a person. Research peptides sold for laboratory use are intended strictly for in vitro or non-human research applications by qualified personnel — not for human consumption, self-administration, or any therapeutic purpose. If you're evaluating a GLP-2-related research compound, confirm identity and purity the way you would for any other lot: check the certificate of analysis against how to read a COA, understand the purity standards a legitimate vendor should be reporting against, and use our lot verification tool to confirm a specific batch's third-party HPLC results before you rely on it in any protocol. Browse current research compounds for COA-backed, lot-tracked material.